Please ensure Javascript is enabled for purposes of website accessibility

2 Risky Robinhood Stocks to Sell Right Now

By Will Ebiefung – Aug 13, 2020 at 8:29AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Don't let these struggling companies shatter your investment portfolio.

The Robinhood stock-trading service is a great resource for novice investors because of its low fees and user-friendly mobile app. But if you are new to the stock market, it can be hard to tell the good companies from the bad ones. That can lead to novice investors easily falling victim to money-burning stocks that will blow up their portfolio. 

One way novice investors look for good stock investing bets is to see what stocks are the most popular and Robinhood helps in that effort by providing lists of the most widely held stocks among its users. There are plenty of good companies on that list and a few that are not so good (and not much to differentiate them within the app).

Here are two extremely risky stocks that are very popular on Robinhood. The first stock is Eastman Kodak (KODK -2.69%), a once-bankrupt film company trying to pivot toward pharmaceuticals production. And the second stock is AMC Entertainment (AMC -14.52%), a movie theater operator that might not survive the coronavirus pandemic because of its troublesome business model. Let's go over what exactly makes these companies terrible investments. 

Hundred dollar bill on fire.

Image source: Getty Images.

1. Eastman Kodak 

Eastman Kodak doesn't have a track record of success. The company filed for Chapter 11 bankruptcy protection in 2012 after failing to adapt to the migration toward digital cameras (a product it helped invent). After restructuring, Kodak pivoted to digital image printing and what can best be described as a harebrained cryptocurrency scheme. Now, it wants to use its vast, underutilized manufacturing footprint to make key starting materials for pharmaceutical products.  

The good news is that Kodak may receive a $765 million loan through the Defense Production Act to produce generic drug ingredients to help with the fight against COVID-19. The bad news is that the company looks unlikely to properly execute on this new opportunity because of its poor management and weak financial condition.

The loan has also been put on hold due to allegations of wrongdoing. The SEC has launched a probe into whether Kodak's management violated insider trading laws because of unusual trading activity before the loan deal was announced. 

This is not the first time Kodak has tried (and failed) to get into the drug business. In 1988, the film company purchased Sterling-Winthrop Pharmaceuticals for $5.1 billion -- only to sell it components off six years later to Sanofi and SmithKline Beecham (now GlaxoSmithKline) for $1.68 billion and $2.93 billion respectively. That ends up being $500 million less than what Kodak initially paid for the business, and it suggests there may have been some value destruction and mismanagement involved. 

In 2019, Kodak reported substantial doubt about its ability to continue as a going concern due to cash flow challenges, and the company generated a net loss of $111 million in the first quarter of fiscal 2020. Many Robinhood investors enjoy taking risks, but in the case of Eastman Kodak, the risks seem to outweigh the potential rewards. 

2. AMC Entertainment

The movie theater industry is in secular decline, and the coronavirus pandemic has accelerated this trend -- putting movie theater operators like AMC Entertainment at serious risk of bankruptcy. The stock has already fallen 62% year to date, and it faces more downside as studios move important releases to their streaming platforms. 

Most recently, Walt Disney (DIS -1.39%) announced plans to release the much-anticipated Mulan on a premium version of Disney+ for $30 on Sept. 4. While this is a steep price point, it is competing against an average theater ticket cost of $9.26 -- and people usually don't go to the movies alone. On top of that, Disney can make up for lower sales value through its higher profit share (Industry sources say studios get about 60% of the cut for a theatrical release, but the studio would get about 100% of revenue from a release on its own service). 

If Mulan's streaming premiere is successful, that could open the door for more studios to skip theaters altogether and release their movies via in-house streaming platforms instead. 

AMC reported second-quarter earnings on Aug. 6, and the results were a disaster. Revenue fell 99%, from $1.5 billion to $18.9 million, and the company generated a net loss of $561 million, which comes out to $5.44 per share. With a stock price of $4.14 at the time of writing, AMC Entertainment lost more than the value of its entire market cap in a single quarter -- a fact that highlights the dangers of holding this stock. 

Will Ebiefung has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Walt Disney. The Motley Fool recommends GlaxoSmithKline and recommends the following options: long January 2021 $60 calls on Walt Disney and short October 2020 $125 calls on Walt Disney. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eastman Kodak Stock Quote
Eastman Kodak
$4.71 (-2.69%) $0.13
AMC Entertainment Holdings, Inc. Stock Quote
AMC Entertainment Holdings, Inc.
$6.83 (-14.52%) $-1.16
The Walt Disney Company Stock Quote
The Walt Disney Company
$98.12 (-1.39%) $-1.38

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.